Table 2.
Parameter estimates and bootstrap results for the OS models
| Parameters | Population estimate (%SEE) | Bootstrap parameter results (5–95 percentile) | ||
|---|---|---|---|---|
| Cmin1 model | Cavg model | Cmin1 model | Cavg model | |
| Baseline hazard | ||||
| BaseHazard | 0.00205 (2.18) | 0.00203 (2.26) | 0.00206 (0.00158–0.00280) |
0.00204 (0.00156–0.00277) |
| Olaratumab effect | ||||
| EMAX | 0.765 (8.63) | 0.756 (9.07) | 0.771 (0.625–0.884) | 0.761 (0.607–0.876) |
| ECmin150 (µg/mL) | 66.1 (12.1) | – | 65.9 (50.9–80.3) | – |
| ECavg50 (µg/mL) | – | 134 (6.72) | – | 135 (115–163) |
| Hill | 8 (fixed) | 8 (fixed) | 8 (fixed) | 8 (fixed) |
| Covariate effects | ||||
| EGRPBase | 0.862 (42.1) | 0.802 (44.0) | 0.925 (0.273–1.83) | 0.857 (0.220–1.72) |
| PRVTRTBase | − 0.583 (15.9) | − 0.535 (19.1) | − 0.57 − (0.740–0.345) | − 0.528 − (0.706–0.282) |
OS overall survival, SEE standard error of the estimate, Cmin1 trough serum concentration at the end of Cycle 1, Cavg average concentration over patient’s entire treatment, EMAX maximum response achievable from a dose, ECmin150 olaratumab Cmin1 yielding a 50% decrease in the baseline hazard, ECavg50 olaratumab Cavg yielding a 50% decrease in the baseline hazard, EGRPBase covariate effect of ECOG status on the baseline hazard, PRVTRTBase covariate effect of the number of prior treatment on the baseline hazard